LIVAGEN 20 MG

Livagen 20 mg – Peptide Hubs

Livagen is a short peptide derived from thymic and liver tissue, classified as a gene expression regulatory peptide. It has been extensively studied in the context of DNA repair, chromatin remodeling, and cellular senescence. Peptide Hubs delivers a research-grade 20 mg vial of lyophilized Livagen designed for advanced anti-aging, epigenetic, and immunomodulatory studies.

Mechanism of Action

Livagen exerts its biological effects by influencing histone acetylation and DNA methylation, thereby modulating gene expression related to cellular longevity, inflammation, and tissue regeneration. It is known to interact with heterochromatin structures, supporting genomic stability and suppressing age-associated transcriptional errors. This PubMed study on Livagen explores its function in DNA repair and immunoregulation.

Primary Research Applications

• DNA repair and epigenetic regulation studies
• Senescence and longevity-focused models
• Immune modulation and thymic support protocols
• Tissue regeneration and chromatin remodeling experiments

Livagen is often stacked with FOX04-DRI for senescence-clearing synergy or Humanin for mitochondrial repair and neuroprotection. It may also be integrated into antioxidant or DNA repair-focused stacks using L-Glutathione or GHK Basic.

Suggested Experimental Use

• Dosage: 10–20 mg per week, split into 2–3 sessions
• Administration: Subcutaneous or intramuscular injection
• Cycle Duration: 4–12 weeks depending on research focus

Stacking Recommendations

• DSIP – to support sleep and circadian-linked gene expression recovery
• B7-33 – for fibrosis control and tissue rejuvenation
• Chonluten – to support immune modulation and epithelial repair
• Semaglutide – for metabolic stability under genomic stress

Safety & Legal Status

Livagen is a synthetic research peptide not approved for human or veterinary use. It is used in laboratory environments for epigenetic and regenerative exploration. It poses no hepatotoxicity, hormonal suppression, or aromatization risk. For insights on related studies, refer to ongoing data at ClinicalTrials.gov.

Frequently Asked Questions